Dual Diagnosis Treatment

Dual Diagnosis Treatment: Integrated Care for Substance Use and Mental Health

Between 35–60% of people with substance use disorders also have depression, anxiety, PTSD, bipolar disorder, or other mental health conditions (estimates vary by study population). Dual diagnosis (co-occurring disorders) significantly complicates treatment and requires integrated, simultaneous care of both conditions.

At KwikPsych, Dr. Monika Thangada specializes in dual diagnosis treatment, providing comprehensive psychiatric and addiction psychiatry care that addresses both the substance use disorder and co-occurring mental health conditions in parallel.

What Is Dual Diagnosis?

Dual diagnosis refers to the presence of:

• Substance Use Disorder (SUD) + One or more psychiatric disorders

Common combinations:

• Alcohol use disorder + major depressive disorder
• Opioid use disorder + anxiety disorder
• Cannabis use disorder + social anxiety disorder
• Methamphetamine use disorder + bipolar disorder
• Alcohol use disorder + PTSD
• Benzodiazepine dependence + generalized anxiety disorder

Critically important: These are not two separate problems to be treated sequentially; they interact and reinforce each other. Integrated treatment is essential.

Why Dual Diagnosis Is Challenging

The Chicken-and-Egg Problem: Which Came First?

Primary mental health condition + substance use as self-medication:

• A person with depression, anxiety, or trauma may begin using substances to relieve symptoms (self-medication)
• Over time, substance use becomes problematic and itself contributes to worsening mental health
• Treatment must address the underlying psychiatric condition AND the substance use

Substance-induced psychiatric symptoms:

• Chronic substance use itself causes depression, anxiety, paranoia, or other psychiatric symptoms
• These symptoms may resolve with sustained abstinence but require time (weeks to months)
• May need psychiatric medication during this time

Mutual reinforcement:

• Untreated depression increases relapse risk (person uses to escape depressed mood)
• Untreated anxiety increases relapse risk (person uses to manage anxiety)
• Active substance use worsens depression and anxiety
• Each condition exacerbates the other

Complexity of Treatment

Sequential treatment fails:

• Treating only the mental health condition while ignoring substance use usually fails (person relapses due to untreated substance use disorder)
• Treating only substance use while ignoring mental health often fails (person returns to substance use to manage untreated psychiatric symptoms)

Medication interactions:

• Some psychiatric medications are contraindicated with certain substances or MAT medications
• Withdrawal from some substances is dangerous and complicated
• Dosing and timing of medications must account for both conditions

Behavioral challenges:

• Depression and anxiety may make engagement in therapy difficult
• Impulsivity from mental health conditions may interfere with treatment adherence
• Motivation to change may be complicated by psychiatric symptoms

Expertise required:

• Effective dual diagnosis treatment requires providers trained in both addiction psychiatry and general psychiatry
• Single-focus treatment (addiction only or mental health only) is insufficient

Common Dual Diagnosis Combinations

Substance Use + Major Depressive Disorder (MDD)

Prevalence: 30-40% of people with alcohol use disorder also have depression

Patterns:

• Depression-first: Person develops depression → uses substances to self-medicate → substance use becomes problematic
• Substance-induced: Heavy substance use (especially alcohol) → secondary depression develops
• Genetic/biological: Shared vulnerability to both conditions

Why this combination is problematic:

• Depressive symptoms (hopelessness, anhedonia, worthlessness) reduce motivation for recovery
• Alcohol is a depressant; chronic use worsens depressive symptoms even though it's initially used for relief
• Suicide risk is substantially elevated among people with co-occurring substance use and depression
• Relapse is common when depression is untreated

Treatment approach:

• Psychiatric medication: SSRIs (sertraline, paroxetine, escitalopram) or SNRIs (venlafaxine) are first-line; bupropion may help (plus some anti-craving effects)
• Timing: Some providers wait for abstinence before starting antidepressants; others start concurrently; current evidence supports starting early if depression is significant
• Behavioral therapy: CBT for both depression and substance use; behavioral activation (structured engagement in activities) is helpful
• Medication-assisted treatment: Appropriate medications reduce withdrawal and cravings, allowing focus on treating depression
• Monitoring: Suicide risk assessment at every visit
• Timeline: Antidepressant effects take 4-6 weeks; brain chemistry improves with abstinence over weeks-months; patience and persistence critical

Substance Use + Anxiety Disorders

Prevalence: 15-25% of people with anxiety disorders also have substance use disorder

Types of anxiety in SUD:

• Generalized anxiety disorder (GAD): Persistent worry about multiple topics
• Panic disorder: Recurrent unexpected panic attacks
• Social anxiety disorder: Fear of social situations
• Specific phobias: Fear of specific situations or objects

Substance misuse patterns:

• Alcohol is commonly used to manage anxiety (social drinking to relax, drinking to manage panic)
• Benzodiazepines may start with legitimate prescription, then misuse develops
• Cannabis used to manage anxiety symptoms
• Stimulants can trigger anxiety but may be used to self-medicate if anxiety manifests as low energy

Why this combination is problematic:

• Alcohol and benzodiazepines provide short-term anxiety relief but worsen anxiety long-term (rebound anxiety)
• Substance withdrawal increases anxiety
• Untreated anxiety increases relapse risk
• Benzodiazepine dependence is particularly difficult (medical detoxification must be slow to prevent seizures)

Treatment approach:

• First-line psychiatric medication: SSRIs (paroxetine, sertraline) are FDA-approved for multiple anxiety disorders and work well in people with SUD
• Other anxiolytics: Buspiron (non-addictive, safe in SUD), hydroxyzine (short-term only), propranolol (for performance anxiety)
• Avoid benzodiazepines if possible due to addiction risk; if necessary, use only short-term during acute crisis with close monitoring
• Behavioral therapy: CBT for anxiety including exposure therapy, breathing techniques, interoceptive exposure (exposure to anxiety sensations)
• Medication-assisted treatment: Reduces substance cravings and withdrawal, allowing focus on anxiety symptoms
• Lifestyle: Exercise is particularly effective for anxiety; regular activity reduces anxiety naturally
• Timeline: Antianxiety effects develop over weeks; exposure therapy requires repeated practice

Substance Use + PTSD (Post-Traumatic Stress Disorder)

Prevalence: 30-50% of people with PTSD also have substance use disorder

Common pattern: Person experiences trauma → develops PTSD symptoms → uses substances to manage symptoms → substance use disorder develops

PTSD symptoms people attempt to manage with substances:

• Intrusive memories/flashbacks → use substances to numb memories
• Nightmares → use alcohol to sleep or substances to suppress REM sleep
• Hyperarousal (hypervigilance, exaggerated startle) → use depressants to calm
• Emotional numbing → use stimulants to feel something
• Avoidance → use substances to avoid triggers

Why this combination is problematic:

• Avoidance (core PTSD symptom) is reinforced by substance use (using to avoid trauma reminders)
• Substance use prevents processing of trauma memories (blocking the therapeutic exposure necessary for healing)
• Trauma-related triggers (reminders, anniversaries) can precipitate intense cravings and relapse
• Hyperarousal may continue even when substance use stops (requires specific PTSD treatment)
• Complex interplay: treating PTSD may increase painful emotions, increasing relapse risk; not treating PTSD increases relapse

Treatment approach:

• Psychiatric medication: SSRIs (sertraline, paroxetine—both FDA-approved for PTSD); prazosin (particularly for nightmares); other medications addressing hyperarousal
• Trauma-focused behavioral therapy:
• Cognitive processing therapy (CPT): Processing traumatic memories and changing thoughts about trauma
• Prolonged exposure (PE): Gradual, repeated confrontation with trauma memories and triggers
• EMDR (eye-movement desensitization and reprocessing): Reprocessing trauma while engaging in bilateral stimulation
• Timing: Typically begin after stabilization in recovery; may be phased approach (stabilization → trauma processing)
• Substance use treatment: MAT and behavioral therapy for SUD
• Grounding techniques: Teaching skills for managing flashbacks and hyperarousal without substances
• Timeline: PTSD treatment is gradual; trauma processing can take months; patience and skilled providers critical

Substance Use + Bipolar Disorder

Prevalence: 50% of people with bipolar disorder have substance use disorder (higher than general population)

Why this combination develops:

• Substance use is more common in bipolar disorder (impulsivity, risk-taking in manic episodes)
• People may self-medicate depressive episodes with stimulants or depressive episodes with alcohol
• Substance use triggers mood episodes (stimulants can trigger mania; alcohol can trigger depression)
• Dopamine disruption from substance use can destabilize mood regulation

Substance-specific concerns:

• Stimulants (cocaine, methamphetamine, ADHD medications): Trigger or worsen manic episodes; extremely dangerous
• Alcohol: Destabilizes mood; common self-medication for depressive episodes
• Cannabis: Can trigger psychosis in vulnerable individuals; can trigger mood episodes
• Benzodiazepines: May seem helpful for manic agitation but can interfere with mood stabilizers

Why this combination is problematic:

• Active substance use interferes with mood stabilizers' effectiveness
• Manic episodes involve poor judgment, high-risk behaviors, impulsivity (substance use, reckless decisions)
• Depressive episodes reduce motivation for treatment adherence
• Dual diagnosis bipolar-SUD has worse prognosis than either condition alone
• Suicide risk is extremely elevated (bipolar disorder + substance use + depression)

Treatment approach:

• Mood stabilizers are essential:
• Lithium (gold standard; requires blood level monitoring and kidney function monitoring)
• Valproic acid/Depakote (requires baseline and periodic liver function monitoring)
• Lamotrigine (particularly for bipolar depression)
• Atypical antipsychotics (quetiapine, olanzapine, aripiprazole, risperidone)
• Substance use treatment: MAT and behavioral therapy; careful medication selection (avoid stimulant ADHD medications; bupropion only with mood stabilizer coverage)
• Behavioral therapy: CBT modified for bipolar disorder; psychoeducation about triggers; relapse prevention for both mood episodes and substance use
• Strict abstinence: Essential; active substance use is incompatible with mood stability
• Intensive monitoring: Regular appointments, mood tracking, substance use monitoring; safety planning
• Hospitalization if needed: For acute manic or depressive episodes, severe withdrawal, or suicide risk
• Timeline: Mood stabilization takes weeks; substance use recovery ongoing; long-term medication maintenance typical

Substance Use + ADHD (Attention-Deficit/Hyperactivity Disorder)

Prevalence: ADHD present in 15-25% of people with substance use disorders

Pattern:

• ADHD → difficulties with impulse control, attention, executive function → self-medication with stimulants (cocaine, methamphetamine) or alcohol/cannabis for impulsivity
• Stimulant use feels self-medicating (improves focus and attention) → addiction develops

Why this combination is problematic:

• Untreated ADHD impairs judgment, impulse control, ability to plan → relapse risk
• Stimulant medications (if needed for ADHD) must be carefully managed in person with SUD history
• Substance use worsens executive dysfunction and impulsivity

Treatment approach:

• ADHD assessment: Determine if ADHD is truly present vs. substance-induced executive dysfunction (requires evaluation and often period of abstinence to clarify)
• ADHD medication: If ADHD confirmed:
• Longer-acting formulations preferred (lower abuse potential than immediate-release)
• Atomoxetine (non-stimulant ADHD medication) may be preferred if high addiction risk
• Bupropion (antidepressant with ADHD benefits; no addiction potential) may be used
• Careful monitoring; consider dispensing to trusted family member
• Avoid if active substance use
• Substance use treatment: MAT and behavioral therapy addressing both SUD and ADHD
• Behavioral interventions: Structure, accountability, external organization tools (calendars, reminders)
• Timeline: ADHD treatment ongoing; impulse control improves with substance use recovery and treatment

Integrated Treatment Model

Effective dual diagnosis treatment integrates care across psychiatric and substance use domains:

Comprehensive Initial Assessment

• Psychiatric evaluation: Detailed mental health history, current symptoms, past treatments, family history
• Substance use evaluation: Detailed use history, severity assessment, withdrawal risk
• Medical evaluation: Physical exam, lab work, assessment for medical comorbidities
• Functional assessment: Impact on work, relationships, self-care
• Risk assessment: Suicide and self-harm risk, abuse history, trauma

Concurrent Treatment

Both conditions are treated simultaneously, not sequentially:

Psychiatric medication management:

• Antidepressants, anxiolytics, mood stabilizers, antipsychotics as indicated
• Careful selection considering interactions with substance use and MAT

Medication-assisted treatment:

• For opioid or alcohol use disorder as indicated
• Reduces withdrawal and cravings, allowing focus on psychiatric symptoms

Individual therapy:

• Addresses both substance use and psychiatric symptoms
• CBT for depression and anxiety; trauma-focused therapy for PTSD; psychoeducation for bipolar disorder
• Integrated rather than separate sessions

Group therapy:

• Dual diagnosis groups (combining SUD and mental health focus) if available
• Peer support and shared experience

Medication adherence:

• Critical for both psychiatric medications and MAT
• Pill organizers, reminders, supervised dosing if needed
• Regular monitoring

Monitoring:

• Regular appointments (weekly initially, tapering to monthly)
• Symptom assessment for both conditions
• Medication side effects
• Substance use (random drug screens)
• Suicide risk monitoring
• Life functioning (work, relationships, self-care)

Supporting Factors

Family involvement:

• Education about both conditions
• Support and boundary-setting
• Family therapy if relationships are significantly affected

Lifestyle factors:

• Sleep: Essential for mood stability and substance use recovery
• Exercise: Reduces depression and anxiety, improves mood, reduces cravings
• Nutrition: Brain function affected by diet; alcohol and stimulants deplete nutrients
• Stress management: Yoga, meditation, grounding techniques
• Social connection: Peer support groups, treatment community, family

Addressing life problems:

• Housing stability: Homelessness worsens both conditions
• Employment/vocation: Purpose and structure
• Legal issues: Court-ordered treatment, probation compliance
• Financial: Managing consequences of substance use or psychiatric episodes
• Physical health: Managing co-occurring medical conditions

Levels of Dual Diagnosis Care

Outpatient care:

• Individual psychiatry appointments for medication management
• Referral to licensed therapist for behavioral therapy
• Support groups or group therapy
• Appropriate for mild-moderate dual diagnosis with good support system

Intensive outpatient (IOP):

• 9+ hours per week structured programming
• Group therapy, individual therapy, skills training
• Psychiatric monitoring
• Appropriate for moderate-severe dual diagnosis or failed outpatient treatment

Partial hospitalization (PHP):

• Daytime program with psychiatric and therapeutic support
• Appropriate for dual diagnosis with significant psychiatric symptoms (active suicidality, severe depression, manic episode)

Inpatient hospitalization:

• 24-hour psychiatric and medical monitoring
• Appropriate for acute psychiatric crisis (suicidality, psychosis), dangerous withdrawal, severe intoxication
• Stabilization then transition to lower level of care

Medications in Dual Diagnosis Treatment

For Depression + Substance Use

First-line antidepressants:

• SSRIs: Sertraline, paroxetine, escitalopram, citalopram
• Advantages: Effective, well-tolerated, not addictive, low overdose risk
• Side effects: Sexual dysfunction, sleep changes, nausea (usually temporary)
• Start low, go slow (lower initial doses, slower increases in people with SUD history)

• SNRIs: Venlafaxine, duloxetine
• Advantages: Effective, particularly for pain and anxiety
• Disadvantages: Discontinuation syndrome if stopped abruptly; higher blood pressure

• Bupropion:
• Advantages: Activating (good for depressive apathy), anti-craving effects for cocaine/stimulants, no sexual dysfunction
• Disadvantages: Contraindicated with seizure disorder, stimulating (not ideal if anxiety), lowers seizure threshold in withdrawal
• Doses up to 300 mg/day

• Mirtazapine:
• Advantages: Sedating (helps sleep), appetite stimulation
• Disadvantages: Weight gain, daytime sedation

Timeline: 4-6 weeks for full antidepressant effect; some improvement within 1-2 weeks

For Anxiety + Substance Use

First-line anxiolytics:

• SSRIs/SNRIs: Same as above; effective for anxiety disorders
• Paroxetine and sertraline FDA-approved for various anxiety disorders

• Buspiron:
• Advantages: Non-addictive, safe in SUD, non-sedating, good for chronic anxiety
• Disadvantages: Slower onset (2-4 weeks), modest effects
• Doses 15-60 mg/day

• Hydroxyzine:
• Advantages: Sedating, non-addictive
• Disadvantages: Short-acting, anticholinergic effects
• Short-term only (acute anxiety)

• Propranolol:
• Beta-blocker; effective for performance anxiety, physical anxiety symptoms
• Non-addictive

Avoid benzodiazepines unless absolutely necessary (acute crisis) and with close supervision

For PTSD + Substance Use

First-line medications:

• SSRIs: Sertraline and paroxetine FDA-approved for PTSD
• Prazosin: Alpha-1 antagonist; particularly effective for PTSD nightmares
• 2-4 mg at bedtime; can titrate to 5-20 mg
• Very few side effects; non-addictive

Therapy is essential: Medications help but trauma-focused therapy (exposure, CPT, EMDR) is critical

For Bipolar Disorder + Substance Use

Mood stabilizers are essential:

• Lithium:
• Gold standard for bipolar disorder
• Requires blood level monitoring (therapeutic range 0.6-1.2 mEq/L)
• Requires baseline and periodic kidney function tests
• Effective but requires monitoring
• Doses 900-1800 mg/day

• Valproic acid (Depakote):
• Effective for mania, some depression benefit
• Requires baseline and periodic liver function tests
• Weight gain possible
• Doses 250-500 mg three times daily

• Lamotrigine:
• Particularly helpful for bipolar depression
• Requires slow titration (risk of rash); typical 100-200 mg daily
• Fewer side effects than lithium/depakote

• Atypical antipsychotics:
• Quetiapine, olanzapine, aripiprazole, risperidone
• Used for acute mania, some also effective for depression
• Metabolic side effects possible (weight gain, glucose effects)

All mood stabilizers essential for stability; substance use incompatible with achieving stability

Recovery and Prognosis in Dual Diagnosis

Challenges:

• More complex course than either condition alone
• Higher relapse rates if untreated
• Greater functional impairment
• Elevated suicide risk

Factors predicting better outcomes:

• Early, integrated treatment
• Sustained engagement in treatment
• Strong family support
• Medication adherence
• Stable housing and employment
• Active participation in therapy and peer support
• Treatment that addresses both conditions simultaneously

Timeline:

• Acute crisis management: Days to weeks
• Stabilization: Weeks to months
• Recovery and rebuilding: Months to years
• Many people require ongoing treatment indefinitely

Relapse is common but not failure: 40-60% of people experience relapse. Returning to treatment, adjusting medications, intensifying therapy all help.

KwikPsych's Dual Diagnosis Approach

At KwikPsych, we provide:

• Comprehensive dual diagnosis evaluation: Screening for both substance use and psychiatric disorders
• Integrated treatment planning: Addressing both conditions simultaneously
• Medication management: Psychiatric medications, MAT medications, careful monitoring
• Psychiatric expertise: Board-certified psychiatrist trained in both addiction and general psychiatry
• Therapist referrals: Connection with licensed therapists specializing in dual diagnosis
• Care coordination: Communication between psychiatrist and therapist
• Ongoing monitoring: Regular follow-up, adjustments to treatment as needed
• Insurance coverage: 10+ major carriers accepted
• Telehealth: Available across Texas
• Self-pay options: $299 initial; $179 follow-up

Contact Us

KwikPsych Psychiatry

Dr. Monika Thangada, MD

12335 Hymeadow Dr, Ste 450

Austin, TX 78750

Phone: 737-367-1230

Telehealth: Available across Texas

Insurance: Aetna, BCBS, Cigna, UnitedHealthcare, Superior HealthPlan/Ambetter, Baylor Scott & White, Oscar, First Health Network, Optum, Medicare

Crisis Support:

• Suicide & Crisis Lifeline: 988
• SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
• Emergency: 911

Disclaimer: This content is for educational purposes and is not a substitute for professional medical advice. Dual diagnosis requires individualized assessment and treatment by qualified professionals. If you're in crisis, please contact emergency services or the Suicide & Crisis Lifeline.